This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tinley, T. L. Articles by Mooberry, S. L. Search for Related Content PubMed PubMed Citation Articles by Tinley, T. L. Articles by Mooberry, S. L.

Novel 2-Methoxyestradiol Analogues with Antitumor Activity¹

Departments of Physiology and Medicine [T. L. T., R. M. L., D. A. R-H., S. L. M.] and Organic Chemistry [J. W. C., P. N. R.], Southwest Foundation for Biomedical Research, San Antonio, Texas 78227, and Cancer Research Center of Hawaii, Honolulu, Hawaii 96813 [L. R. W.]

2-Methoxyestradiol (2-ME2) is a natural estrogen metabolite that, while devoid of estrogenic effects, has both antiangiogenic and antitumor effects. 2-ME2 is currently being evaluated in Phase I and Phase II clinical trials for the treatment of multiple types of cancer. Novel analogues of 2-ME2 were tested for activities that predict antiangiogenic and antitumor effects. Selected analogues were tested for inhibitory activity against endothelial cell proliferation and invasion. The results show that these analogues are effective inhibitors of endothelial cell activities that may predict antiangiogenic activity, and one analogue, 2-methoxy-14-dehydroestradiol (14-dehydro-2-ME2), was 6–15-fold more potent than the parental compound in these assays. The analogues were also evaluated for inhibition of proliferation and cytotoxicity against multiple tumor cell lines and found to be potent and effective. 14-Dehydro-2-ME2 was approximately 15-fold more potent than 2-ME2 against various tumor cell lines, and 2-methoxy-15-dehydroestradiol was particularly effective against DU 145 and PC3 prostate cancer cell lines. In vivo antitumor activity was observed for the three analogues tested in the murine xenograft MDA-MB-435 model; however, 2-ME2 provided no antitumor activity in this trial. The two most effective analogues, 14-dehydro-2-ME2 and 2-methoxyestradiol-15,16-acetonide, provided 29.4% and 26.7% inhibition of tumor burden, respectively. Mechanism of action studies indicate that the analogues cause mitotic spindle disruption, mitotic arrest, microtubule depolymerization, and inhibition of the assembly of purified tubulin similar to the effects of 2-ME2. Consistent with antimitotics that inhibit the dynamic instability of tubulin and initiate apoptosis, these novel 2-ME2 analogues cause Bcl-2 phosphorylation and activation of mitogen-activated protein kinase signaling pathways.

This article has been cited by other articles:

				T. M. LaVallee, P. A. Burke, G. M. Swartz, E. Hamel, G. E. Agoston, J. Shah, L. Suwandi, A. D. Hanson, W. E. Fogler, C. F. Sidor, et al. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198 Mol. Cancer Ther., June 1, 2008; 7(6): 1472 - 1482. [Abstract] [Full Text] [PDF]

				J.-B. Shen and A. J. Pappano An Estrogen Metabolite, 2-Methoxyestradiol, Disrupts Cardiac Microtubules and Unmasks Muscarinic Inhibition of Calcium Current J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 507 - 512. [Abstract] [Full Text] [PDF]

				L. A Kingsley, P. G J Fournier, J. M Chirgwin, and T. A Guise Molecular Biology of Bone Metastasis Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 443 - 457. [Abstract] [Full Text] [PDF]

				S. van den Driesche, V. M Smith, M. Myers, and W C. Duncan Expression and regulation of oestrogen receptors in the human corpus luteum Reproduction, April 1, 2008; 135(4): 509 - 517. [Abstract] [Full Text] [PDF]

				S. V. Rajkumar, P. G. Richardson, M. Q. Lacy, A. Dispenzieri, P. R. Greipp, T. E. Witzig, R. Schlossman, C. F. Sidor, K. C. Anderson, and M. A. Gertz Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma Clin. Cancer Res., October 15, 2007; 13(20): 6162 - 6167. [Abstract] [Full Text] [PDF]

				L. A. Kingsley, P. G.J. Fournier, J. M. Chirgwin, and T. A. Guise Molecular Biology of Bone Metastasis Mol. Cancer Ther., October 1, 2007; 6(10): 2609 - 2617. [Abstract] [Full Text] [PDF]

				S. L. Mooberry, K. N. Weiderhold, S. Dakshanamurthy, E. Hamel, E. J. Banner, A. Kharlamova, J. Hempel, J. T. Gupton, and M. L. Brown Identification and Characterization of a New Tubulin-Binding Tetrasubstituted Brominated Pyrrole Mol. Pharmacol., July 1, 2007; 72(1): 132 - 140. [Abstract] [Full Text] [PDF]

				Y. Gui, H. Yin, J.-Y. He, S.-H. Yang, M. P. Walsh, and X.-L. Zheng Endoreduplication of human smooth muscle cells induced by 2-methoxyestradiol: a role for cyclin-dependent kinase 2 Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1313 - H1320. [Abstract] [Full Text] [PDF]

				A. Basu, V. P. Castle, M. Bouziane, K. Bhalla, and S. Haldar Crosstalk between Extrinsic and Intrinsic Cell Death Pathways in Pancreatic Cancer: Synergistic Action of Estrogen Metabolite and Ligands of Death Receptor Family. Cancer Res., April 15, 2006; 66(8): 4309 - 4318. [Abstract] [Full Text] [PDF]

				C. Sidor, R. D'Amato, K. D. Miller, A. Stewart, T. E. Sutherland, M. Schuliga, T. Harris, L. Quan, D. McAllister, B. Pool, et al. The Potential and Suitability of 2-Methoxyestradiol in Cancer Therapy Clin. Cancer Res., August 15, 2005; 11(16): 6094 - 6096. [Full Text] [PDF]

				T. E. Sutherland, M. Schuliga, T. Harris, B. L. Eckhardt, R. L. Anderson, L. Quan, and A. G. Stewart 2-Methoxyestradiol Is an Estrogen Receptor Agonist That Supports Tumor Growth in Murine Xenograft Models of Breast Cancer Clin. Cancer Res., March 1, 2005; 11(5): 1722 - 1732. [Abstract] [Full Text] [PDF]

				J. A. Mobley, J. O. L'Esperance, M. Wu, C. J. Friel, R. H. Hanson, and S.-M. Ho The novel estrogen 17{alpha}-20Z-21-[(4-amino)phenyl]-19-norpregna-1,3,5(10),20-tetraene-3,17{beta}-diol induces apoptosis in prostate cancer cell lines at nanomolar concentrations in vitro Mol. Cancer Ther., May 1, 2004; 3(5): 587 - 596. [Abstract] [Full Text] [PDF]